These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 36301749)
21. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY]. Fukunaga A; Morita E; Miyagi T; Eto K; Shimizu A; Kagami S; Yamamoto H; Vardi M; Tang Y; Wang Y; Hide M Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020 [TBL] [Abstract][Full Text] [Related]
22. Consensus on treatment goals in hereditary angioedema: A global Delphi initiative. Maurer M; Aygören-Pürsün E; Banerji A; Bernstein JA; Balle Boysen H; Busse PJ; Bygum A; Caballero T; Castaldo AJ; Christiansen SC; Craig T; Farkas H; Grumach AS; Hide M; Katelaris CH; Li HH; Longhurst H; Lumry WR; Magerl M; Martinez-Saguer I; Riedl MA; Zhi Y; Zuraw B J Allergy Clin Immunol; 2021 Dec; 148(6):1526-1532. PubMed ID: 34048855 [TBL] [Abstract][Full Text] [Related]
23. Health-related quality of life among children with hereditary angioedema. Engel-Yeger B; Farkas H; Kivity S; Veszeli N; Kőhalmi KV; Kessel A Pediatr Allergy Immunol; 2017 Jun; 28(4):370-376. PubMed ID: 28258590 [TBL] [Abstract][Full Text] [Related]
24. Long-term prophylaxis of hereditary angioedema with a pasteurized C1 inhibitor concentrate. Tallroth GA Int Arch Allergy Immunol; 2011; 154(4):356-9. PubMed ID: 20975289 [TBL] [Abstract][Full Text] [Related]
25. Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence. Bork K; Machnig T; Wulff K; Witzke G; Prusty S; Hardt J Orphanet J Rare Dis; 2020 Oct; 15(1):289. PubMed ID: 33059692 [TBL] [Abstract][Full Text] [Related]
26. A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE). Bork K Clin Rev Allergy Immunol; 2016 Oct; 51(2):183-92. PubMed ID: 27207174 [TBL] [Abstract][Full Text] [Related]
28. The safety of treatments for angioedema with hereditary C1 inhibitor deficiency. Zanichelli A; Wu MA; Andreoli A; Mansi M; Cicardi M Expert Opin Drug Saf; 2015; 14(11):1725-36. PubMed ID: 26429506 [TBL] [Abstract][Full Text] [Related]
29. Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children. Reshef A; Grivcheva-Panovska V; Kessel A; Kivity S; Klimaszewska-Rembiasz M; Moldovan D; Farkas H; Gutova V; Fritz S; Relan A; Giannetti B; Magerl M Pediatr Allergy Immunol; 2019 Aug; 30(5):562-568. PubMed ID: 30993784 [TBL] [Abstract][Full Text] [Related]
30. An evidence based therapeutic approach to hereditary and acquired angioedema. Bork K Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):354-62. PubMed ID: 24983294 [TBL] [Abstract][Full Text] [Related]
31. Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients. Federici C; Perego F; Borsoi L; Crosta V; Zanichelli A; Gidaro A; Tarricone R; Cicardi M BMJ Open; 2018 Jul; 8(7):e022291. PubMed ID: 30061443 [TBL] [Abstract][Full Text] [Related]
32. Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema. Bork K Immunotherapy; 2014; 6(5):533-51. PubMed ID: 24635050 [TBL] [Abstract][Full Text] [Related]
33. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate. Zuraw BL; Cicardi M; Longhurst HJ; Bernstein JA; Li HH; Magerl M; Martinez-Saguer I; Rehman SM; Staubach P; Feuersenger H; Parasrampuria R; Sidhu J; Edelman J; Craig T Allergy; 2015 Oct; 70(10):1319-28. PubMed ID: 26016741 [TBL] [Abstract][Full Text] [Related]
34. Hereditary angioedema with normal C1 inhibitor and factor XII mutation: a series of 57 patients from the French National Center of Reference for Angioedema. Deroux A; Boccon-Gibod I; Fain O; Pralong P; Ollivier Y; Pagnier A; Djenouhat K; Du-Thanh A; Gompel A; Faisant C; Launay D; Bouillet L Clin Exp Immunol; 2016 Sep; 185(3):332-7. PubMed ID: 27271546 [TBL] [Abstract][Full Text] [Related]
36. Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema. Craig T; Feuersenger H; Pragst I; Dang J Allergy Asthma Proc; 2022 May; 43(3):202-208. PubMed ID: 35524357 [No Abstract] [Full Text] [Related]
37. Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema. Henry Li H; Riedl M; Kashkin J Clin Rev Allergy Immunol; 2019 Apr; 56(2):207-218. PubMed ID: 29909591 [TBL] [Abstract][Full Text] [Related]
38. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. Craig T; Magerl M; Levy DS; Reshef A; Lumry WR; Martinez-Saguer I; Jacobs JS; Yang WH; Ritchie B; Aygören-Pürsün E; Keith PK; Busse P; Feuersenger H; Pawaskar D; Jacobs I; Pragst I; Doyle MK Lancet; 2022 Mar; 399(10328):945-955. PubMed ID: 35219377 [TBL] [Abstract][Full Text] [Related]
39. Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert Bouillet L; Boccon-Gibod I; Gompel A; Floccard B; Martin L; Blanchard-Delaunay C; Launay D; Fain O Eur J Dermatol; 2017 Apr; 27(2):155-159. PubMed ID: 28251901 [TBL] [Abstract][Full Text] [Related]